Volker Limmroth

10.9k total citations · 1 hit paper
137 papers, 6.7k citations indexed

About

Volker Limmroth is a scholar working on Pathology and Forensic Medicine, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Volker Limmroth has authored 137 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Pathology and Forensic Medicine, 64 papers in Psychiatry and Mental health and 27 papers in Physiology. Recurrent topics in Volker Limmroth's work include Migraine and Headache Studies (60 papers), Multiple Sclerosis Research Studies (44 papers) and Trigeminal Neuralgia and Treatments (34 papers). Volker Limmroth is often cited by papers focused on Migraine and Headache Studies (60 papers), Multiple Sclerosis Research Studies (44 papers) and Trigeminal Neuralgia and Treatments (34 papers). Volker Limmroth collaborates with scholars based in Germany, United States and Switzerland. Volker Limmroth's co-authors include Zaza Katsarava, HC Diener, Hans‐Christoph Diener, G. Fritsche, H Kaube, Arne May, Markus Jüptner, Cornelius Weiller, Rudolf van Schayck and H.H. Coenen and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Neuroscience.

In The Last Decade

Volker Limmroth

130 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brain stem activation in spontaneous human migraine attacks

1995 1.0k citations Volker Limmroth et al. profile →

Peers

Countries citing papers authored by Volker Limmroth

Since Specialization

Citations

This map shows the geographic impact of Volker Limmroth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Volker Limmroth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Volker Limmroth more than expected).

Fields of papers citing papers by Volker Limmroth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Volker Limmroth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Volker Limmroth. The network helps show where Volker Limmroth may publish in the future.

Co-authorship network of co-authors of Volker Limmroth

This figure shows the co-authorship network connecting the top 25 collaborators of Volker Limmroth. A scholar is included among the top collaborators of Volker Limmroth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Volker Limmroth. Volker Limmroth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increase of nitrous oxide-induced neurological disorders – a German multicenter experience 2025 ·Neurological Research and Practice ·Julius N. Meißner, (unknown), (unknown), Matthias Rehm, (unknown), (unknown), Sebastian Paus, Volker Limmroth, Gereon R. Fink, Gabor C. Petzold, (unknown)	3
2	Status epilepticus and benzodiazepine treatment: Use, underdosing and outcome - insights from a retrospective, multicentre registry 2023 ·Seizure ·(unknown), (unknown), (unknown), Gereon R. Fink, Volker Limmroth, Lothar Burghaus, Michael P. Malter	3
3	Prehospital Levetiracetam Use in Adults With Status Epilepticus: Results of a Multicenter Registry 2023 ·Journal of Clinical Neurology ·Lothar Burghaus, (unknown), (unknown), (unknown), Volker Limmroth, Gereon R. Fink, Michael P. Malter	1
4	Autoinjector preference among patients with multiple sclerosis: results from a national survey 2017 ·Patient Preference and Adherence ·Volker Limmroth, Joachim Reischl, Bhupinder Mann, (unknown), (unknown), (unknown), Thomas Schreiner	9
5	Durable suppression of disease activity by alemtuzumab in the absence of continuous treatment over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II) 2016 ·Multiple Sclerosis Journal ·Christopher LaGanke, J. de Sèze, M. S. Freedman, Mario Habek, Raymond Hupperts, Volker Limmroth, R. Macdonell, Krzysztof Selmaj, David Margolin, K. Thangavelu, Eva Havrdová	1
6	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab 2016 ·BMC Neurology ·Tjalf Ziemssen, Achim Gass, Jens Wuerfel, Antonios Bayas, Björn Tackenberg, Volker Limmroth, Ralf A. Linker, Mathias Mäurer, Judith Haas, Martin Stangel, (unknown), (unknown), Hans‐Peter Hartung	10
7	Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS) 2016 ·Multiple Sclerosis and Related Disorders ·Axel Meißner, Volker Limmroth	15
8	Case Report 2015 ·Medicine ·(unknown), Kathrin Gerbershagen, (unknown), (unknown), Michael Brockmann, Verena Schildgen, (unknown), Volker Limmroth, Arno J. Dormann, Oliver Schildgen	6
9	Treatment of Relapsing-Remitting Multiple Sclerosis: Current and Future Algorithms 2014 ·European Neurology ·Volker Limmroth	3
10	Oral Triptans in the Preventive Management of Cluster Headache 2012 ·Current Pain and Headache Reports ·L Pageler, Volker Limmroth	4
11	Frovatriptan for Prophylactic Treatment of Cluster Headache: Lessons for Future Trial Design 2010 ·Headache The Journal of Head and Face Pain ·L Pageler, Zaza Katsarava, Christian Lampl, Andreas Straube, Stefan Evers, Hans‐Christoph Diener, Volker Limmroth	24
12	Bedeutung der gesundheitsbezogenen Lebensqualität und Religiosität für die Akzeptanz von chronischen Schmerzen 2008 ·Der Schmerz ·Kathrin Gerbershagen, (unknown), Jens Kuhn, Volker Limmroth, H. Bewermeyer	8
13	Prevalence and Severity of Multiple-Sclerosis-Associated Fatigue in Treated and Untreated Patients 2007 ·European Neurology ·Norman Putzki, Zaza Katsarava, (unknown), Hans‐Christoph Diener, Volker Limmroth	42
14	GABAergic Drugs for the Treatment of Migraine 2007 ·CNS & Neurological Disorders - Drug Targets ·(unknown), Volker Limmroth	12
15	Quality Assessment in Multiple Sclerosis Therapy (QUASIMS) 2007 ·Journal of Neurology ·Volker Limmroth, R. Maleßa, Uwe K. Zettl, Jürgen Koehler, (unknown), (unknown), (unknown), (unknown), Andrea Viehöver, Uwe Meier, (unknown), Joerg Hasford, Norman Putzki, (unknown), (unknown), (unknown)	51
16	Symptomatic Migraine and Pontine Vascular Malformation 2006 ·Cephalalgia ·Mark Obermann, Elke R. Gizewski, Volker Limmroth, HC Diener, Zaza Katsarava	32
17	CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis 2006 ·Journal of Neuroimmunology ·(unknown), Norman Putzki, Volker Limmroth, Ralph Remus, Monika Lindemann, Dietmar Knop, Norbert Mueller, Cornelia Hardt, E. Kreuzfelder, Hans Grosse‐Wilde	114
18	Balo's concentric sclerosis 2002 ·Journal of Neurology ·Oliver Kastrup, Philipp Stude, Volker Limmroth	35
19	Analgesics 2001 ·Current Medical Research and Opinion ·Hans‐Christoph Diener, Volker Limmroth	7
20	Acute management of migraine: triptans and beyond 1999 ·Current Opinion in Neurology ·Hans‐Christoph Diener, Volker Limmroth	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact